Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05947136
Other study ID # PASCA-MM (ET22000285)
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 19, 2024
Est. completion date September 14, 2027

Study information

Verified date February 2024
Source Centre Leon Berard
Contact Romain BUONO, PharmaD, MPH
Phone +33469856358
Email romain.buono@lyon.unicancer.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, multicentre, phase III, randomised, controlled intervention study. Two groups of patients with equal numbers will be studied and each patient will be allocated to one of the two groups described below by randomisation (ratio 1:1). Each patient will be allocated to one of the two groups described below by randomisation (ratio 1:1). - PASCA interventional group For both the 7 complications of interest (primary objective) and the 13 secondary complications (secondary objective), a specific and proactive referral will be made systematically after each screening assessment, depending on the level of risk, estimated according to decision trees (management guide) and through the dedicated PASCA network of healthcare professionals, in order to initiate early treatment and follow-up if necessary. - Control group For the 7 complications of interest (primary objective) as well as for the 13 complications (secondary objective): all the data from each identification check-up will be sent to the onco-haematological transmitted to the referring onco-haematologists, so that they can initiate their own management. => For all patients, regardless of group All patients will receive four screening assessments covering the 7 complications of interest and 13 secondary complications: - Visit No.1 (T1), 1-2 months after the autologous haematopoietic stem cell transplantation (aHSCT), corresponding to the patient's visit to his or her Multiple Myeloma (MM) monitoring consultation and/or the start of his or her consolidation treatment. - Visit No.2 (T2), 4 months after aHSCT, corresponding to a patient's visit for the end of consolidation treatment; - Visit No.3 (T3), 14 months after the last aHSCT, corresponding to a visit by the patient during his or her maintenance treatment; - Visit No.4 (T4), 24 months after the last aHSCT, corresponding to a visit by the patient for a MM monitoring consultation.


Description:

After each screening visit, all patients randomised to the intervention group will receive the PASCA intervention: 1. An interpretation of the results of the screening tests concerning - the 7 complications of interest assessed at T1, T2, T3 and T4 ; - the 13 secondary complications assessed at T1, T3 and T4. This interpretation will be based on decision trees (1 tree/complication) to guide investigators in their decision-making and to standardise orientations; 2. Explanation of results and referrals to the patient using plain language, by a phone call, ; 3. Early, proactive care via a dedicated network of healthcare professionals.


Recruitment information / eligibility

Status Recruiting
Enrollment 204
Est. completion date September 14, 2027
Est. primary completion date June 14, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Age = 18 years old and = 70 years old. 2. Patient treated in an investigation center. 3. Symptomatic multiple myeloma eligible for autologous hematopoietic stem cell transplantation (HSCT). 4. In stringent complete response, complete response, very good complete response, or partial before HSCT. 5. First induction-type treatment (Isa-KRD/dara-VRD/dara-VTD/VRD/VTD), intensification therapy with melphalan, HSCT, consolidation, maintenance including at least one drug immunomodulator. 6. ECOG performance status WHO = 2. 7. No history or coexistence of other primary cancer apart from basal cell cancer cutaneous 8. Able to understand, read and write French. 9. Having signed and dated the informed consent. Exclusion Criteria: 1. Unable to be monitored for medical, social, family, geographical or psychological, throughout the duration of the study. 2. Deprived of liberty by court or administrative decision. 3. Not affiliated with a health insurance plan. 4. Not having declared an attending physician. 5. Not domiciled in the Auvergne-Rhône-Alpes region or in the Saône-et-Loire department. 6. Not available and/or not willing to participate in the project for the entire duration of the study. 7. Pregnant women, breastfeeding women, people in emergency situations, people incapable of personally giving their consent including adults under guardianship

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Interpretation of the results from the detection visit
- An interpretation of the results of the detection tests concerning the 7 complications of interest assessed at T1, T2, T3 and T4 ; the 13 secondary complications assessed at T1, T3 and T4. This interpretation will be based on decision trees (1 tree/complication) to guide investigators in their decision-making and to standardise orientations;
Explaining detection results and referrals to the patient
Explanation of results and directions to the patient using plain language;The aims of this call are as follows: Clearly explain the results of the detection visit and the action to be taken for each referral; Evaluate the help to be given to the patient. This help will consist of making bookings with a healthcare professional in the PASCA network; Reassure patients about their results, but also make them aware of the importance of taking action to improve or prevent the onset of complications.
Early medical care through the network
Early, proactive medical care through a network of dedicated healthcare professionals.
Transmission of results from each detection visit to the referring onco-haematologists - Control Group
For both the 7 complications of interest (primary objective) and the 13 secondary complications (secondary objective): all the data from each detection visit will be sent to the referring onco-haematologists, so that they can initiate their own management.

Locations

Country Name City State
France Centre Léon Bérard Lyon

Sponsors (2)

Lead Sponsor Collaborator
Centre Leon Berard National Cancer Institute, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary change from Baseline high blood pressure blood pressure = 140/90 mmHg measured in the investigating center and persisting over time month 2, month 4, month 14 and month 24
Primary Change from Baseline chronic kidney failure incidence at 24 months diagnosed on the basis of 2 blood tests carried out within 3 months with the same technique showing either:
a decrease in GFR to < 60ml/min/1.73m2, estimated from serum creatinine using the CKD-EPI equation (Chronic Kidney Disease EPIdemiology collaboration, Levey, 2009),
positive proteinuria or albuminuria (albuminuria/creatinine ratio),
haematuria with a GR > 10/mm3 or 10,000/ml (after eliminating a urological cause),
leucocyturia with a WBC >10/mm3 or 10,000/ml (in the absence of infection),
a morphological abnormality on renal ultrasound: size asymmetry, bumpy contours, small kidneys or large polycystic kidneys, nephrocalcinosis, cyst.
The evolutionary character corresponds to one of the following situations:
Annual decline in GFR = 5 ml/min/1.73 m²/year: GFR year n - GFR year n+1
Presence of albuminuria,
Poorly controlled arterial hypertension
month 2, month 4, month 14 and month 24
Primary Change from Baseline chronic pain incidence at 60 months pain felt for more than 3 months by the patient with an intensity on the Visual Analogue Scale (VAS) = 3 month 2, month 4, month 14 and month 24
Primary Change from Baseline sexual disorders incidence at 24 months at least one perceived problem among the following:
disorders of desire,
arousal/erection disorders in men,
arousal disorders (insufficiency) in women,
Orgasm disorders in women
month 2, month 4, month 14 and month 24
Primary Change from Baseline osteoporosis incidence at 24 months T-score evaluated by osteodensitometry, on the lumbar spine and upper end of the femur month 2, month 14 and month 24
Primary Change from Baseline chronic fatigue incidence at 24 months Questionnaire "MFI-20" (Multidimensional Fatigue Inventory) month 2, month 4, month 14 and month 24
Primary Change from Baseline severe anxiety disorder incidence at 24 months Questionnaire "HADS-D" (Hospital Anxiety and Depression scale) month 2, month 4, month 14 and month 24
Secondary Change from Baseline depressive events incidence at 24 months Defined by at least two main depressive symptoms, associated with at least two symptoms additional information, according to the 2017 HAS recommendation "Characterized depressive episode in adults
: care in first resort".
month 2, month 4, month 14 and month 24
Secondary Change from Baseline physical deconditioning incidence at 24 months Defined by at least two tests among the 6 min Walk Test (TDM6), Handgrip-test, 60s Sit-to-stand, Flamingo test, with usual values below the norms defined by their authors, according to age and sex month 2, month 14 and month 24
Secondary Change from Baseline cognitive problems incidence at 24 months Positive score on at least one of the sub-dimensions of the Functional questionnaire Cancer Therapy Assessment - Cognitive Function (FACT-COG) month 2, month 14 and month 24
Secondary Change from Baseline hypogonadism incidence at 24 months Presence of clinical signs as defined by the International Society for Sexual Medicine
A value below the lower limit on at least one of the following blood assay:
level of total testosterone
level of bioavailable testosterone
month 2, month 14 and month 24
Secondary Change from Baseline obesity incidence at 24 months BMI value:
[25-30[ kg/m2 with a waist circumference above the norm (= 94cm for men or
= 80cm for women)
= 30 kg/m2
month 2, month 14 and month 24
Secondary Change from Baseline hypothyroidism incidence at 24 months level of thyroid-stimulating hormone
level of total thyroxine
month 2, month 14 and month 24
Secondary Change from Baseline dyslipidemias incidence at 24 months hypercholesterolemia (LDL) = 1.6 g/L estimated by the Friedewald formula and/or a hypertriglyceridemia = 4 g/L month 2, month 14 and month 24
Secondary Change from Baseline Heart failure markers incidence at 24 months NT-proBNP and/or troponin I level above the threshold values. month 2, month 14 and month 24
Secondary Change from Baseline Atrial fibrillation incidence at 24 months equivocal electrocardiogram, interpreted by an experienced physician month 2, month 14 and month 24
Secondary Change from Baseline of respiratory failure markers incidence at 24 months FVC, FVC, FEV1, FEF25-75, FEF50, FEF25 (established by spirometric test) = 80% of the predicted values (abacus on age, sex, height and origin ethnic) month 2, month 14 and month 24
Secondary Change from Baseline return to work issues incidence at 24 months Diagnosed by a social worker month 2, month 14 and month 24
Secondary Change from Baseline of Lifestyle risk factors ( tobacco, alcohol, and cannabis) incidence at 24 months consumption :
smoking and/or active cannabis
alcohols higher than the latest recommendations
month 2, month 4, month 14 and month 24
Secondary Change from baseline Myelodysplastic syndromes and secondary acute leukemia incidence at 24 months confirmed by the reference diagnosis month 4, month 14 and month 24
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1